What do early stage companies really need to focus on? Patent attorney David Dykeman says, first and foremost, that it’s intellectual property protection.
Dykeman –who co-chairs Greenberg Traurig’s global Life Sciences & Medical Technology Group – will speak at DeviceTalks Boston on October 2.
We asked him to give us some ideas on the important issues surrounding M&A and patenting.
MDO: What’s going on in M&A? What are you seeing in the medtech industry?
Dykeman: After a couple years of major consolidations in the industry, we’re seeing those work their way through the system. There is still a very strong appetite for M&A among the major players buying up these smaller and earlier stage companies. I think companies that are addressing a large market and an unmet medical need are particularly attractive for acquisition.